|
A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients Clinical research trials and A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients. A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients clinical trial. Test subjects oftentimes recieve the best healthcare possible for their A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): Merck Research Laboratories ,
Synopsis: The purpose of this study is to determine if two dose levels of indinavir combined with two nucleoside analogue reverse transcriptase inhibitors (NRTIs) have the same effect on plasma viral load (level of HIV in the blood).
Details: In this open-label study 350 seropositive HIV-1 men and women are first stratified according to baseline plasma viral RNA (less than 400 copies/mL vs negative plasma viral RNA result) then randomized into one of two arms: Arm 1: Indinavir (800 mg, q8h) plus two pre-existing NRTIs. Arm 2: Indinavir (1,200 mg, q12h) plus two pre-existing NRTIs. Plasma viral RNA will be measured every 4 weeks for the duration of the 24-week study.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Documented HIV-1 seropositive status. - CD4 count greater than 100 cells/mm3. - Parental consent for patients under 18.
Total Enrollment: 350
Location and Contact Information:
Tower ID Med Associates
Los Angeles, California, 90048
United States
San Francisco Gen Hosp / UCSF AIDS Program
San Francisco, California, 94110
United States
1917 Research Clinic
Birmingham, Alabama, 35294
United States
Anderson Clinical Research
New York City, New York, 10016
United States
Univ of Miami School of Medicine
Miami, Florida, 33136
United States
Univ of Utah School Of Medicine / Div of Infec Disease
Salt Lake City, Utah, 84132
United States
Natl Naval Med Ctr / Special Immunology Clinic
Bethesda, Maryland, 20889
United States
SUNY / Health Science Ctr at Brooklyn
Brooklyn, New York, 11203
United States
Education & Research Building
Camden, New Jersey, 08103
United States
Akron City Hospital
Akron, Ohio, 44304
United States
Univ Health Ctr 7D
Detroit, Michigan, 48201
United States
Kansas City Free Health Clinic
Kansas City, Missouri, 64111
United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, 30308
United States
Garden State Infectious Diseases / E I P Kennedy Health Sys
Voorhees, New Jersey, 08043
United States
HIV Clinical Research
Ft. Lauderdale, Florida, 33316
United States
CRIA
New York City, New York, 10001
United States
Brigham and Women's Hosp
Boston, Massachusetts, 02115
United States
St Vincents Hosp and Med Ctr / Div of HIV Med
New York City, New York, 10011
United States
Albany Med College / Div of HIV Medicine
Albany, New York, 12208
United States
Boston Med Ctr / Clinical Research Office
Boston, Massachusetts, 02118
United States
Rush Presbyterian St Lukes Med Ctr
Chicago, Illinois, 60612
United States
Northwestern Univ Med School
Chicago, Illinois, 60611
United States
New York Hosp of Queens / AIDS Ctr
Flushing, New York, 11355
United States
Ctr for AIDS Research / Education and Service (CARES)
Sacramento, California, 95814
United States
Kaiser Permanente / Infectious Disease
Los Angeles, California, 90027
United States
Houston Clinical Research Network / Southhampton Med Group
Houston, Texas, 77098
United States
Thomas Jefferson Univ
Philadelphia, Pennsylvania, 19107
United States
Ponce de Leon Ctr
Atlanta, Georgia, 30308
United States
Anderson Clinical Research
Pittsburgh, Pennsylvania, 15213
United States
Additional Information:
Study ID Numbers: 246P; MK-0639
Study Start Date:
Record last reviewed: June 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002406
Other Hiv Infections Studies:
1. A Study of Delavirdine Used Together with Other Anti-HIV Drugs in HIV-Infected Patients
2. A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
3. Safety and Effectiveness of Giving L-743,872 to Patients with Thrush That Has Not Been Cured With Fluconazole
4. A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients
5. The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used with or without Clofazimine in the Treatment of MAC in Patients with AIDS
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
|
|
|
|
|
|
|
|